Collegium Pharmaceutical: Buying The Projected Growth For 2026 [Seeking Alpha]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Seeking Alpha
COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio remains a stable cash generator, with authorized generics providing a smart revenue stream and mitigating immediate generic erosion risks. I maintain a disciplined trading approach, with a Buy Threshold at $30.33 and Sell Level 1 at $39.89, awaiting volatility-driven entry opportunities. This idea was discussed in more depth with members of my private investing community, Compounding Healthcare. Learn More » Dougal Waters/DigitalVision via Getty Images My last Collegium Pharmaceutical ( COLL article was back in late 2022, where I discussed how the company was gaining momentum and had plenty of upside following their BDSI acquisition. At that time, Xtampza ER was More on my IG service Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these i
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Swings [Yahoo! Finance]Yahoo! Finance
- Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual ConferenceGlobeNewswire
- Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 [Yahoo! Finance]Yahoo! Finance
- Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? [Yahoo! Finance]Yahoo! Finance
- Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? [Yahoo! Finance]Yahoo! Finance
COLL
Earnings
- 11/6/25 - Beat
COLL
Sec Filings
- 1/8/26 - Form 8-K
- 12/30/25 - Form 8-K
- 12/17/25 - Form 144
- COLL's page on the SEC website